Biocon Share Price in Focus on 9 July 2026 as Company Publishes Phase III INSIGHT Clinical Data Supporting Yesafili
- July 9, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Biocon publishes two peer reviewed Phase III INSIGHT studies on aflibercept biosimilar Yesafili for diabetic macular edema. Stock at Rs 399.85, up 0.71%. Yesafili FDA approved May 2024.
The Biocon share price is in focus on 9 July 2026 after the company announced the publication of two important clinical studies supporting the effectiveness of Yesafili, its aflibercept biosimilar. The data from the Phase III INSIGHT program evaluating MYL-1701P appeared in two peer reviewed journals, adding to the clinical evidence base for the treatment of diabetic macular edema.
Click Here – Get Free Investment Predictions
What Biocon Announced on Yesafili
Biocon said the newly published data contributes to the clinical evidence base supporting the development of aflibercept MYL-1701P for diabetic macular edema, a leading cause of vision loss linked to diabetes. MYL-1701P was approved and its vial format was granted interchangeable designation under the name Yesafili by the US Food and Drug Administration in May 2024.
The Phase III INSIGHT study compared Yesafili with the reference product Eylea and found no clinically meaningful differences in pharmacokinetics, safety, efficacy, or immunogenicity, reinforcing the biosimilar’s clinical profile ahead of its broader commercial rollout.
Biocon Share Price Snapshot on 9 July 2026
The Biocon share price snapshot below reflects early trade levels.
| Metric | Value |
|---|---|
| Last traded price | Rs 399.85 |
| Change | +0.71 percent |
| Intraday high | Rs 401.25 |
| Intraday low | Rs 397.90 |
Get Pharma Sector Views from SEBI Registered Investment Advisors
Why This Matters for Biocon’s Ophthalmology Push
Yesafili is central to Biocon Biologics’ expansion into ophthalmology, an area the company entered following approvals in Europe, the UK, Canada, and the US. Biocon separately reached a settlement with Regeneron that clears the way to commercialize Yesafili in the US market by the second half of 2026 or earlier. Fresh published clinical evidence typically supports physician and payer confidence as biosimilars scale in a new therapy area.
Download the Univest iOS App or Univest Android App to track the Biocon share price live and get pharma sector updates.
Conclusion
The publication of Phase III INSIGHT data adds to Biocon’s clinical case for Yesafili as it prepares for a fuller US launch. With the Biocon share price trading in a narrow range around Rs 400, investors should watch for further updates on the US commercial rollout timeline and volume ramp up in the ophthalmology segment.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions FAQs
Why is the Biocon share price in focus today?
Ans. The Biocon share price is in focus on 9 July 2026 after the company announced the publication of two important clinical studies in peer reviewed journals supporting the effectiveness of Yesafili, its aflibercept biosimilar.
What is Yesafili and what does it treat?
Ans. Yesafili, known generically as aflibercept-jbvf, is Biocon’s biosimilar of Eylea and is used to treat diabetic macular edema and other retinal conditions such as wet age related macular degeneration.
What did the Phase III INSIGHT study data show?
Ans. The Phase III INSIGHT program evaluating MYL-1701P, the aflibercept biosimilar behind Yesafili, found no clinically meaningful differences versus the reference product Eylea in pharmacokinetics, safety, efficacy, and immunogenicity in patients with diabetic macular edema.
When was Yesafili approved by the FDA?
Ans. Yesafili, marketed under the MYL-1701P molecule, was approved by the US Food and Drug Administration in May 2024, and the vial format was granted interchangeable designation under the same approval.
What was the Biocon share price today?
Ans. Biocon was quoting at Rs 399.85, up 0.71 percent, having touched an intraday high of Rs 401.25 and a low of Rs 397.90 in early trade.
Why does published clinical data matter for a biosimilar company like Biocon?
Ans. Peer reviewed publication strengthens the clinical evidence base for regulators, physicians, and payers, which can support broader prescriber confidence and market uptake of a biosimilar such as Yesafili in key markets like the US.
